CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

ARBs and/or ACE inhibitorsWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug3386 observational Wiki 0.58
drug3029 Usual Care Wiki 0.35

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Angiotensin II Type 1 Receptor Blockers (ARBs) on Outcomes of Coronavirus Infection?

The coronavirus (COVID-19) pandemic continues to grow exponentially. Angiotensin II levels are increased in human influenza and are associated with influenza viral load, disease progression and mortality. Preliminary data shows angiotensin II receptor blockers (ARBs) limits lung injury in murine influenza H7N9, as well as viral titre and RNA. ARBs could limit viral titre and organ injury in COVID-19. We will therefore collect clinical chart data and test angiotensin II levels of patients who are admitted to ICU with COVID-19 to determine whether there is a correlation between taking ARBs and clinical outcomes in these patients. Other blood biomarkers and clinical risk factors for COVID-19 have come to light in recent weeks. We include these in our observational analysis to help generate an understanding of COVID-19 presentation and blood biomarker characterization of disease.

NCT04510623 COVID-19 SARS-CoV2 Other: ARBs and/or ACE inhibitors Other: Usual Care
MeSH:Coronavirus Infections

Primary Outcomes

Measure: COVID-19 WHO ordinal scale

Time: 14 days

Secondary Outcomes

Measure: Organ Dysfunction

Time: 14 days

Measure: 28-day mortality

Time: 29 days or less (may be discharged from critical care before day 28)

Measure: Hospital/ICU length of stay

Time: 29 days or less (may be discharged before day 28)

Measure: ICU admission

Time: 29 days or less (may be discharged from critical care before day 28)

No related HPO nodes (Using clinical trials)